ArticleNature communications2026
Engineering the paclitaxel biosynthetic pathway in Physcomitrium patens for de novo and stable biosynthesis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Paclitaxel is a highly valuable diterpenoid anticancer drug originally extracted from the yew tree. Due to the low efficiency of plant extraction and the high cost of semi-synthesis, efforts have been made to produce paclitaxel through biosynthesis. However, there have been no reports to date on engineered strains capable of paclitaxel biosynthesis. Here, we engineer a paclitaxel-producing line using the moss (Physcomitrium patens) chassis cells by combining transient expression verification, cytoplasmic localization strategies, self-cleaving 2 A peptide-mediated multi-gene co-expression systems and a modular iterative transformation strategy for stable genetic inheritance. Even after continuous subculturing multiple times, the engineered paclitaxel-producing lines obtained through both the initial reconstructed pathway and the optimized pathway are able to stably produce paclitaxel. This study proposes that Physcomitrium patens can serve as a plant chassis for paclitaxel biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.